In vivo distribution and antitumour activity of liposomal 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine

References

• Van Borssum Waalkes M., Scherphof G.L. Liposome-incorporated 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine as a slow-release antitumor drug depot in rat liver macrophages. Selective Cancer Therapeutics 1990; 6: 15–22
   PubMedGoogle Scholar
• Bottcher C.J.F., Van Gent C.M., Pries C. A rapid and sensitive sub-micro phosphorus determination. Analytica Chimica Acta 1961; 24: 203–204
   Web of Science ®Google Scholar
• Daemen T., Dontje B.H.J., Veninga A., Scherphof G.L., Oosterhuis J.W. Therapy of murine liver metastases by administration of MDP encapsulated in liposomes. Selective Cancer Therapeutics 1990; 6: 63–71
   PubMedGoogle Scholar
• Ensminger W.D., Rosowski A., Raso V., Levin D.C., Glode M., Come S., Steele G., Frei E. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Research 1978; 38: 3784–3792
   PubMed Web of Science ®Google Scholar
• Fichtner I., Arndt D. Stand und Perspektiven der Liposomenforschung. Pharmazie 1989; 44(H11)752–757
   PubMed Web of Science ®Google Scholar
• Fichtner I., Arndt D., Reszka R. Antineoplastic activity and toxicity of some alkylating cytostatics (Cyclophosphamide, CCNU, Cytostasan) encapsulated in liposomes in different murine tumour models. Journal of Microencapsulation 1986; 3(2)77–87
   PubMedGoogle Scholar
• Fukushima S., Kawaguchi T., Nishida M., Juni K., Yamashita Y., Takahashi M., Nakano M. Selective anticancer effects of 3′-5′-dioctanoyl-5-fluoro-2′-deoxyuridine, a lipophilic prodrug of 5-fluoro-2′-deoxyuridine, dissolved in an oily lymphographic agent on hepatic cancer of rabbits bearing VX-2 tumour. Cancer Research 1987; 47: 1930–1934
   PubMed Web of Science ®Google Scholar
• Hartmann H.R., Matter A. Antiproliferative action of a novel fluorinated uridine analog, 5′-deoxy-5-fluorouridine, measured in vitro and in vivo on four different murine tumour lines. Cancer Research 1982; 42: 2412–2415
   PubMed Web of Science ®Google Scholar
• Heidelberger C. Fluorinated pyrimidines. Progress in Nucleic Acids Research and Molecular Biology 1965; 4: 1–50
   PubMedGoogle Scholar
• Heidelberger C., Danenberg P.V., Moran R.G. Fluorinated pyrimidines and their nucleosides. Advances in Enzymology 1983; 54: 57–119
   Google Scholar
• Houghton J.A., Houghton P.J., Wooten R.S. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2′-deoxyuridine. Cancer Research 1979; 39: 2406–2413
   PubMed Web of Science ®Google Scholar
• Kanzawa F., Hoshi A., Kuretani K., Saneyoshi M., Kawaguchi T. Antitumour activity of 3′-5′-diesters of 5-fluoro-2′-deoxyuridine against murine leukaemia L1210 cells. Cancer Chemotherapy and Pharmacology 1981; 6: 19–23
   PubMed Web of Science ®Google Scholar
• Kawaguchi T., Suzuki Y., Nakahara Y., Nambu N., Nagai T. Activity of esterase in the hydrolysis of 3′-5′-diesters of 5-fluoro-2′-deoxyuridine in the relation to the structure of the diester prodrugs. Chemical and Pharmaceutical Bulletin 1985; 33(1)301–307
   PubMed Web of Science ®Google Scholar
• Kawaguchi T., Fukushima S., Hayashi Y., Kaneko M., Nakano M. Selective accumulation of 3′-5′-dioctanoyl-5-fluoro-2′-deoxyuridine (FdUrd-C8) and sustained release of its active metabolites in VX-2 rabbit hepatoma following intraarterial administration of FdUrd-C8 solution in Lipiodol. Cancer Research 1988; 48: 4179–4183
   PubMed Web of Science ®Google Scholar
• Maruyama K., Mori A., Kennel S.J., van Borssum Waalkes M., Scherphof G.L., Huang L. Drug delivery by organ-specific immunoliposomes. Polymeric Drugs and Drug Delivery Systems, K. L. Dunn, R. M. Ottenbrite. American Chemical Society. 1991; 275–284
   Google Scholar
• Ostro M.J., Cullis P.R. Use of liposomes as injectable-drug delivery systems. American Journal of Hospital Pharmacy 1989; 46: 1576–1587
   PubMedGoogle Scholar
• Pinedo H.M., Peters G.J. Fluorouracil: biochemistry and pharmacology. Journal of Clinical Oncology 1988; 6(10)1653–1664
   PubMed Web of Science ®Google Scholar
• Poznansky M.J., Juliano R.L. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacological Review 1984; 36(4)277–336
   PubMed Web of Science ®Google Scholar
• Scherphof G.L., Roerdink F., Dijkstra J., Ellens H., De Zanger R., Wisse E. Uptake of liposomes by rat and mouse hepatocytes and Kupffer cells. Biology of the Cell 1983; 47: 47–58
   Web of Science ®Google Scholar
• Scherphof G.L., Daemen T., Derksen J.T.P., Lazar G., Spanjer H.H., Roerdink F.H. In vivo uptake and processing of liposomes by parenchymal and non-parenchymal liver cells. Targeting of Drugs; Anatomical and Physiological Considerations, G. Gregoriadis, S. S. Davis, G. Poste, K. Sikora. Plenum Press, New York-London 1988; 109–120
   Google Scholar
• Schwendener R.A., Supersaxo A., Rubas W., Weder H.G., Hartmann H.R., Schott H., Ziegler A., Hengartner H. 5′-O-palmitoyl- and 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine—novel lipophilic analogues of 5′-fluoro-2′-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results. Biochemical and Biophysical Research Communications 1985; 126(2)660–666
   PubMed Web of Science ®Google Scholar
• Schwendener R.A., Schott H., Hartmann H.R., Supersaxo A., Rubas W., Hengartner H. Liposomen als Trager von lipophilen Cytosinarabinosid- und Fluorodeoxyuridin- Derivaten. Onkologie 1987; 10: 232–239
   PubMedGoogle Scholar
• Simmons S.P., Kraemer P.A. Liposomal entrapment of floxuridine. Journal of Pharmaceutical Sciences 1977; 66: 984–986
   PubMed Web of Science ®Google Scholar
• Storm G., Roerdink F.H., Steerenberg P.A., de Jong W.H., Crommelin D.J.A. Influence of lipid composition on the antitumour activity exerted by doxorubicin-containing liposomes in a rat solid tumour model. Cancer Research 1987; 47: 3366–3372
   PubMed Web of Science ®Google Scholar
• Supersaxo A., Rubas W., Hartmann H.R., Schott H., Hengartner H., Schwendener R.A. The antitumour effect of lipophilic derivatives of 5-fluoro-2′-deoxyuridine incorporated into liposomes. Journal of Microencapsulation 1988; 5(1)1–11
   PubMed Web of Science ®Google Scholar
• Williams W.M., Huang K.C., Chen T.S., Warren B.S. Dose-dependent elimination of 5-fluoro-2′-deoxyuridine in the monkey. Proceedings of the Society for Experimental Biology and Medicine 1987; 184: 326–336
   PubMed Web of Science ®Google Scholar
• Yamashita Y., Takahashi M., Bussaka H., Fukushima S., Kawaguchi T., Nakano M. Intraarterial infusion of 5-fluoro-2-deoxyuridine-C8 dissolved in a lymphographic agent in malignant liver tumours. Cancer 1989; 64(12)2437–2444
   PubMed Web of Science ®Google Scholar